Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

    NEXT STORY
    Turning Point Therapeutics Announces Program Updates and Milestones for 2020
    PREV STORY
    Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Great Basin Scientific Closes $2.7 Million Offering of Units

    SALT LAKE CITY, June 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), ...

    author_avatar
    NASDAQ Market News

    Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

    author_avatar
    NASDAQ Market News

    Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress

    author_avatar
    NASDAQ Market News